Novo Nordisk A/S (NVO)vsProcter & Gamble Company (PG)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
PG
Procter & Gamble Company
$143.92
+0.53%
CONSUMER DEFENSIVE · Cap: $337.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 263% more annual revenue ($309.06B vs $85.26B). NVO leads profitability with a 33.1% profit margin vs 19.3%. PG appears more attractively valued with a PEG of 3.93. PG earns a higher WallStSmart Score of 55/100 (C).
NVO
Buy55
out of 100
Grade: C
PG
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
-211.9%
Fair Value
$45.90
Current Price
$143.92
$98.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Mega-cap, among the largest globally
Every $100 of equity generates 32 in profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 26.3%
Generating 3.8B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
1.5% revenue growth
Expensive relative to growth rate
Earnings declined 5.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : PG
The strongest argument for PG centers on Market Cap, Return on Equity, Altman Z-Score. Profitability is solid with margins at 19.3% and operating margin at 26.3%.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : PG
The primary concerns for PG are Revenue Growth, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
NVO profiles as a declining stock while PG is a value play — different risk/reward profiles.
PG carries more volatility with a beta of 0.34 — expect wider price swings.
PG is growing revenue faster at 1.5% — sustainability is the question.
PG generates stronger free cash flow (3.8B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 55/100), backed by strong 33.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Procter & Gamble Company
CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA
The Procter & Gamble Company (P&G) is an American multinational consumer goods corporation headquartered in Cincinnati, Ohio, founded in 1837 by William Procter and James Gamble. It specializes in a wide range of personal health, consumer health, personal care, and hygiene products; these products are organized into several segments including Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine, & Family Care. Before the sale of Pringles to Kellogg's, its product portfolio also included food, snacks, and beverages.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?